SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010. Available at: http://seer.cancer.gov/csr/1975_2007/ Accessed on October 26, 2011.
  • 2
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 3
    Konety BR, Joyce GF, Wise F. Bladder and upper tract urothelial cancer. In: Litwin MS, Saigal CS, eds. Urologic Diseases in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2007: 223-280.
  • 4
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675.
  • 5
    Ghoneim MA, Abol-Enein H. Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol. 2008; 5: 501-508.
  • 6
    Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009; 374: 239-249.
  • 7
    Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys. 2008; 70: 456-463.
  • 8
    Gallagher DJ, Bajorin DF. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. Nat Clin Pract Urol. 2008; 5: 484-485.
  • 9
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 48: 189-199.
  • 10
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 1927-1934.
  • 11
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005; 48: 202-205.
  • 12
    Bajorin DF, Herr HW. Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradign shift? J Clin Oncol. 2011; 29: 2135-2137.
  • 13
    Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30984 trial. J Clin Oncol. 2011; 29: 2171-2177.
  • 14
    Chang SS, Hassan JM, Cookson MS, Wells N, Smith JAJr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003; 170: 1085-1087.
  • 15
    Liedberg F, Anderson H, Månsson W. Treatment delay and prognosis in invasive bladder cancer. J Urol. 2005; 174: 1777-1781.
  • 16
    Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S; West Midlands Urological Research Group. Delay and survival in bladder cancer. BJU Int. 2002; 89: 868-878.
  • 17
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
  • 18
    Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008; 113: 2471-2477.
  • 19
    Sternberg CN, de Mulder PH, Schornagel JH, et al; European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001; 19: 2638-2646.
  • 20
    von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
  • 21
    Herr HW. Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer. Eur Urol. 2009; 55: 303-305.
  • 22
    Weight CJ, Garcia JA, Hansel DE, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer. 2009; 115: 792-799.
  • 23
    Alva AS, Tallman CT, He C, et al. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: A multidisciplinary approach. Cancer. 2011; doi:10.1002/cncr.26240.
  • 24
    Ghadjar P, Burkhard FC, Gautschi O, Thalmann GN, Studer UE. Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int. 2011; 107: 894-897.
  • 25
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004; 171: 561-569.
  • 26
    Kassouf W, Spiess PE, Brown GA, et al. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007; 52: 769-774.
  • 27
    Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55: 815-825.
  • 28
    Apolo AB, Riches J, Schöder H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010; 28: 3973-3978.
  • 29
    Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging–accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009; 251: 112-121.